Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Current Assets (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Current Assets for 6 consecutive years, with $157.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 46.29% to $157.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $157.2 million through Dec 2025, down 46.29% year-over-year, with the annual reading at $157.2 million for FY2025, 46.29% down from the prior year.
  • Current Assets for Q4 2025 was $157.2 million at TScan Therapeutics, down from $188.2 million in the prior quarter.
  • The five-year high for Current Assets was $299.5 million in Q2 2024, with the low at $100.9 million in Q1 2023.
  • Average Current Assets over 5 years is $190.0 million, with a median of $187.0 million recorded in 2021.
  • The sharpest move saw Current Assets surged 354.53% in 2021, then tumbled 46.29% in 2025.
  • Over 5 years, Current Assets stood at $165.7 million in 2021, then decreased by 25.07% to $124.1 million in 2022, then soared by 56.48% to $194.2 million in 2023, then skyrocketed by 50.7% to $292.7 million in 2024, then crashed by 46.29% to $157.2 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $157.2 million, $188.2 million, and $221.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.